194 related articles for article (PubMed ID: 21129443)
1. Inhibiting TGF-β signaling in hepatocellular carcinoma.
Giannelli G; Mazzocca A; Fransvea E; Lahn M; Antonaci S
Biochim Biophys Acta; 2011 Apr; 1815(2):214-23. PubMed ID: 21129443
[TBL] [Abstract][Full Text] [Related]
2. The TGF-β signaling pathway as a pharmacological target in a hepatocellular carcinoma.
Mazzocca A; Antonaci S; Giannelli G
Curr Pharm Des; 2012; 18(27):4148-54. PubMed ID: 22630081
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
4. TGF-β and Hepatocellular Carcinoma: When A Friend Becomes An Enemy.
Arrese M; Hernandez A; Astete L; Estrada L; Cabello-Verrugio C; Cabrera D
Curr Protein Pept Sci; 2018; 19(12):1172-1179. PubMed ID: 29150921
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Chung CL; Wang SW; Sun WC; Shu CW; Kao YC; Shiao MS; Chen CL
Biochem Pharmacol; 2018 Aug; 154():39-53. PubMed ID: 29678520
[TBL] [Abstract][Full Text] [Related]
6. The rationale for targeting TGF-β in chronic liver diseases.
Giannelli G; Mikulits W; Dooley S; Fabregat I; Moustakas A; ten Dijke P; Portincasa P; Winter P; Janssen R; Leporatti S; Herrera B; Sanchez A
Eur J Clin Invest; 2016 Apr; 46(4):349-61. PubMed ID: 26823073
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.
Giannelli G; Villa E; Lahn M
Cancer Res; 2014 Apr; 74(7):1890-4. PubMed ID: 24638984
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
9. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Fransvea E; Angelotti U; Antonaci S; Giannelli G
Hepatology; 2008 May; 47(5):1557-66. PubMed ID: 18318443
[TBL] [Abstract][Full Text] [Related]
10. Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells.
Wittmann P; Grubinger M; Gröger C; Huber H; Sieghart W; Peck-Radosavljevic M; Mikulits W
BMC Cancer; 2015 Nov; 15():909. PubMed ID: 26573807
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis.
Yamazaki K; Masugi Y; Sakamoto M
Dig Dis; 2011; 29(3):284-8. PubMed ID: 21829019
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
Mazzocca A; Fransvea E; Dituri F; Lupo L; Antonaci S; Giannelli G
Hepatology; 2010 Feb; 51(2):523-34. PubMed ID: 19821534
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
14. TGF-β signaling in onset and progression of hepatocellular carcinoma.
Meindl-Beinker NM; Matsuzaki K; Dooley S
Dig Dis; 2012; 30(5):514-23. PubMed ID: 23108308
[TBL] [Abstract][Full Text] [Related]
15. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.
Neuzillet C; de Gramont A; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Oncotarget; 2014 Jan; 5(1):78-94. PubMed ID: 24393789
[TBL] [Abstract][Full Text] [Related]
16. Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma.
Dooley S; Weng H; Mertens PR
Dig Dis; 2009; 27(2):93-101. PubMed ID: 19546546
[TBL] [Abstract][Full Text] [Related]
17. miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer.
Brockhausen J; Tay SS; Grzelak CA; Bertolino P; Bowen DG; d'Avigdor WM; Teoh N; Pok S; Shackel N; Gamble JR; Vadas M; McCaughan GW
Liver Int; 2015 Jan; 35(1):240-53. PubMed ID: 24576072
[TBL] [Abstract][Full Text] [Related]
18. Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism.
Boye A; Wu C; Jiang Y; Wang J; Wu J; Yang X; Yang Y
J Ethnopharmacol; 2015 Jul; 169():219-28. PubMed ID: 25934513
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
Jiang F; Wang X; Liu Q; Shen J; Li Z; Li Y; Zhang J
Toxicol Lett; 2014 Nov; 231(1):55-61. PubMed ID: 25196641
[TBL] [Abstract][Full Text] [Related]
20. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
